Friday, 6 November 2026European Markets

PEXIP HOLDING Stock Was Up By 10.86% On Monday

Loading stream...

(VIANEWS) - The Market ended the session with PEXIP HOLDING (PEXIP.OL) jumping 10.86% to kr27.98 on Monday while Oslo Børs Benchmark Index_GI rose 0.25% to kr1,267.23.

PEXIP HOLDING's last close was kr25.24, 12.91% below its 52-week high of kr28.98.

About PEXIP HOLDING

Pexip Holding ASA, a video technology company, provides end-to-end video conferencing platform and digital infrastructure worldwide. The company offers self-hosted software application and as-a-service deployment options for enterprise video conferencing, built on its proprietary Infinity technology. Its interoperability solutions are integrated into Microsoft Teams, Skype for Business, and Google Hangouts. The company serves government, healthcare, education, finance, legal, judicial, and retail industries. Pexip Holding ASA was founded in 2011 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, PEXIP HOLDING has a trailing twelve months EPS of kr-0.83.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -5.06%.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is 4.5% and 105.3%, respectively.

More news about PEXIP HOLDING (PEXIP.OL).

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com